Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients.

Jing Zheng,Yanping Zhu,Ke Sun,Qian Shen,Yuehong Wang,He Cao,Analyn Lizaso,Bing Yu,Jing Lin,Songan Chen,Jianya Zhou,Jianying Zhou

Lung Cancer（2020）

引用 2|浏览31

暂无评分

摘要

•The efficacy of crizotinib in ALK positive NSCLC patients are heterogeneous.•The implications of co-occurring mutations in ALK + patients is very limited.•Concurrent deleterious mutations have prognostic implications in ALK+ patients.

查看译文

关键词

ALK,EGFR,EML4,FISH,NGS,NSCLC,OS,PFS,TKI,NR

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要